SKLB-Y13
Based on 1 Customer Validation
SKLB-Y13 is a selective YTHDF1 inhibitor with an IC50 of 0.76 μM and a KD of 5.097 μM. SKLB-Y13 binds to the Tyr397 and Trp470 residues in the m6A-binding pocket of YTHDF1, disrupting the interaction between YTHDF1 and m6A-modified mRNA. SKLB-Y13 inhibits cancer cell proliferation and promotes apoptosis. SKLB-Y13 is applicable to breast cancer-related research.
For research use only. We do not sell to patients.
- Purity: 98.44%
- Formula: C23H21Cl2N7OS
- Molecular Weight:514.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All Caspase Isoforms
More
Biological Activity
|
YTHDF1 0.76 μM (IC50) |
YTHDF2 4.27 μM (IC50) |
YTHDF3 6.17 μM (IC50) |
SKLB-Y13 upregulates m6A levels in MDA-MB-231 cells in a YTHDF1-dependent manner[1].
SKLB-Y13 (0-20 μM) inhibits the viability of MDA-MB-231 and MDA-MB-468 breast cancer cells[1].
SKLB-Y13 significantly inhibits the invasion of MDA-MB-231 and MDA-MB-468 breast cancer cells, and reduces the expression of metastasis-related proteins (MMP9, MMP2, snail and vimentin)[1].
SKLB-Y13 (0-10 μM) induces concentration-dependent apoptosis in MDA-MB-231 and MDA-MB-468 breast cancer cells, accompanied by upregulated expression of Cleaved-Caspase-3 and Cleaved-Parp1[1].
SKLB-Y13 (0-10 μM) dose-dependently downregulates the protein expression of PRPF6, MAP2K6, c-FOS and STK4 in MDA-MB-231 breast cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231, MDA-MB-468, MCF-10A
-
Concentration:0, 5, 10, 15, 20 μM
-
Incubation Time:/
-
Result:Inhibited the viability of MDA-MB-231 (IC50 = 6.05 μM) and MDA-MB-468 (IC50 = 6.34 μM) breast cancer cells, with minimal effect on normal MCF-10A cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BABL/c nude mice treated MDA-MB-231[1]
-
Dosage:10 mg/kg; 20 mg/kg; 40 mg/kg
-
Administration:i.p.; daily; 16 days
-
Result:Significantly reduced tumor volume and tumor weight compared to controls.
Reduced Ki-67-positive cells in a dose-dependent manner.
Increased Cleaved-Caspase-3 and Cleaved-Parp1 levels in a dose-dependent manner.
Significantly downregulated PRPF6, MAP2K6, c-FOS, and STK4 protein expression.
Caused no significant changes in mouse body weight or pathological changes in major organs.
Chemical Information
-
Appearance Solid
-
Molecular Weight 514.43
-
Formula C23H21Cl2N7OS
-
Color Light yellow to yellow
-
SMILES
ClC1=CN=C(N=C1NC2=C(C3=C(S2)CN(CC3)CC4=CC=CC=C4Cl)C(N)=O)C5=CC=NN5C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (194.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9439 mL | 9.7195 mL | 19.4390 mL | 48.5975 mL |
| 5 mM | 0.3888 mL | 1.9439 mL | 3.8878 mL | 9.7195 mL | |
| 10 mM | 0.1944 mL | 0.9719 mL | 1.9439 mL | 4.8597 mL | |
| 15 mM | 0.1296 mL | 0.6480 mL | 1.2959 mL | 3.2398 mL | |
| 20 mM | 0.0972 mL | 0.4860 mL | 0.9719 mL | 2.4299 mL | |
| 25 mM | 0.0778 mL | 0.3888 mL | 0.7776 mL | 1.9439 mL | |
| 30 mM | 0.0648 mL | 0.3240 mL | 0.6480 mL | 1.6199 mL | |
| 40 mM | 0.0486 mL | 0.2430 mL | 0.4860 mL | 1.2149 mL | |
| 50 mM | 0.0389 mL | 0.1944 mL | 0.3888 mL | 0.9719 mL | |
| 60 mM | 0.0324 mL | 0.1620 mL | 0.3240 mL | 0.8100 mL | |
| 80 mM | 0.0243 mL | 0.1215 mL | 0.2430 mL | 0.6075 mL | |
| 100 mM | 0.0194 mL | 0.0972 mL | 0.1944 mL | 0.4860 mL |
SKLB-Y13 Related Classifications
HY-176848 Related Classifications
Powered by Bioz